Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Pulanic
D
D
Cowen
E W
EW
Baird
K
K
Bishop
M R
MR
Pavletic
S Z
SZ
D002908:Chronic Disease; D003131:Combined Modality Therapy; D000069439:Dasatinib; D006086:Graft vs Host Disease / Q000209:etiology* / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012598:Sclerosis; D012720:Severity of Illness Index; D013844:Thiazoles / Q000009:adverse effects*; D055815:Young Adult
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib